5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Emcure Pharmaceuticals Ltd.

•
emcure.comBSE: 544210NSE: EMCURE
Market Cap₹ 36,331 Cr.
Current Price
High / Low₹ 2,048 / 1,260
Stock P/E44.8
Book Value₹ 206
Price to Book8.18
Dividend Yield0.19 %
ROCE24.3 %
ROE21.8 %
Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Promoters have been increasing their shareholding - up 29.8pp over 2 years
  • Latest quarter profit grew 63.0% YoY, showing strong momentum
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.29x)
  • Institutional investors have been accumulating - FII+DII up 7.6pp
  • Company comfortably covers its interest (9.0x coverage)
  • Company has a consistent dividend-paying track record

CONS

  • A large part of profit comes from other income (33.0% of PBT)
  • Total debt has risen sharply - up 108.3% year on year
  • Stock is trading at 8.2x its book value
  • Recurring exceptional / one-off items are inflating headline profit
  • Though reporting repeated profits, the company pays out little dividend (9.3%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY TOTAL MKTNIFTY 500NIFTY SMLCAP 250
S.No.Name
1.SUNPHARMA1868.5037.06448315.740.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9482.7586.06251737.220.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4931.9086.01187593.620.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1129.0024.95112618.180.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1368.0032.79110515.040.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1933.2595.54104455.860.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1690.0026.1997238.860.241032.0325.229150.3517.4412.7620.54
8.LUPIN2092.0017.3095660.020.861416.9816.018276.8934.2828.8629.59
9.DRREDDY1143.2029.6195420.610.70435.60-69.108099.80-5.2113.7510.63
10.MANKIND2266.0045.8293596.020.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2439.5538.2968850.120.10482.83927.884018.4831.3520.3520.03
12.EMCURE1915.2035.9236331.200.19292.4936.172580.4522.8525.2520.64
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
8378888709039701,1051,0291,2781,0971,2611,4181,4681,451
7257887388038519529041,0348691,0651,1181,0961,207
Operating Profit111100132100120152124245228195301372244
OPM %13.32%11.22%15.15%11.06%12.34%13.77%12.09%19.14%20.79%15.48%21.19%25.32%16.79%
213025312855192218521093525
Interest39464239383120242128333733
Depreciation46485456555657576062626363
Profit before Tax483661355511967186166158314306269
Tax %24.34%23.85%20.42%18.33%26.52%27.18%25.35%24.99%25.88%25.51%17.66%23.69%25.52%
Net Profit36274829408750140123118259234200
2.001.513.781.602.234.622.657.376.486.2113.6512.3310.55

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
2,0582,2412,4542,3763,1543,3873,1073,4984,3825,2435,598
1,5751,7141,8831,9522,4102,5932,6693,0563,7594,2214,487
Operating Profit4845285704237437954384426231,0231,111
OPM %23.51%23.54%23.25%17.82%23.57%23.46%14.11%12.63%14.22%19.50%19.85%
-4323569394133119129142287221
Interest10188127137123145167166113118131
Depreciation116120130155156166179205225247250
Profit before Tax2243423702255576162122004289441,047
Tax %2.99%29.11%23.30%22.02%24.57%27.52%24.62%19.55%25.85%22.37%22.62%
Net Profit217243284175420447160161317733810
EPS12.0113.4215.669.6923.2524.718.858.8816.7438.66—
Dividend Payout %24.98%26.07%22.32%25.81%4.30%12.14%22.60%33.79%17.92%9.31%—

COMPOUNDED SALES GROWTH

10 Years:
9%
5 Years:
11%
3 Years:
19%

COMPOUNDED PROFIT GROWTH

10 Years:
10%
5 Years:
12%
3 Years:
66%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
—
1 Year:
44%

RETURN ON EQUITY

10 Years:
16%
5 Years:
15%
3 Years:
14%
Last Year:
22%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Sep 4

₹ 0.36

Rs.3.6000 per share(36%)Final Dividend

2025

Aug 14

₹ 0.30

Rs.3.0000 per share(30%)Final Dividend

2026

Aug 7

₹ 0.36

Rs.3.6000 per share(36%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital181181181181181181181181189190
1,0321,2131,5811,7072,1091,5161,6451,7382,8233,509
1,0601,1221,2401,2511,6681,6871,7831,3428681,520
Trade Payables2223433244395746016738211,1201,140
123209252294331338334675415555
Total Liabilities2,6183,0683,5783,8714,8634,3234,6164,7575,4166,914
8808921,1001,1661,2781,3071,4331,7181,7591,755
Capital Work in Progress28846940632619223925310693110
2983053114088645636906846781,424
5474764964446227307107701,0381,207
00000001,1031,1911,535
Cash & Bank2754293926148141321417
5778721,2371,4891,6471,4351,389343644867
Total Assets2,6183,0683,5783,8714,8634,3234,6164,7575,4166,914

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
391450497416889598590585558424
Cash from Investing-300-287-276-165-831-189-270-171-436-948
Cash from Financing147-217-53-4631-343-55-288-49526
173-10342175-25-104180126731

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Mar 2020Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
48.0178.0877.9477.9277.9177.8877.8777.8777.83
0.002.913.053.062.863.293.593.354.87
13.093.963.873.442.844.366.106.108.46
Government0.000.000.000.000.000.000.000.000.00
38.9015.0515.1415.5716.3914.4612.4412.698.83

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-01
General Updates

2026-09-01 - Intimation under Regulations 30 and 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dispatch of letter to the Members whose e-mail addresses are not registered with the Company/Depository Participants

2026-09-01
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-01 - Emcure Pharmaceuticals Limited has informed the Exchange about Schedule of meet

2026-09-01
Credit Rating

2026-09-01 - Emcure Pharmaceuticals Limited has informed the Exchange about Credit Rating

2026-08-29
Copy of Newspaper Publication

2026-08-29 - Newspaper Advertisement of Notice of the 45th Annual General Meeting and e-voting information

2026-08-28
Shareholders meeting

2026-08-28 - Emcure Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 21, 2026

2026-08-25
ESOP/ESOS/ESPS

2026-08-25 - Emcure Pharmaceuticals Limited has informed the Exchange regarding Allotment of 19100 Shares.

2026-08-12
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-12 - Emcure Pharmaceuticals Limited has informed the Exchange about Transcript

2026-08-08
General Updates

2026-08-08 - Update on USFDA inspection at our formulations facility located at Sanand, Ahmedabad, Gujarat, India.

2026-08-07
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-07 - Emcure Pharmaceuticals Limited has informed the Exchange about Schedule of meet

News

Recent coverage and analyst commentary for EMCURE

Loading news…

🤖

AI Stock Analyst

Emcure Pharmaceuticals Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login